Welcome to our dedicated page for Aim Immunotech news (Ticker: AIMI), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (AIMI/AIM) generates news that reflects its role as an immuno-pharma biotechnology company focused on Ampligen-based therapeutics for cancers, immune disorders and viral diseases, including COVID-19. Company press releases and scientific updates highlight developments in its clinical research, intellectual property portfolio, and stock exchange status, giving investors and observers insight into both scientific progress and corporate milestones.
Recent news has emphasized Ampligen’s role in oncology and immunology research. AIM ImmunoTech has reported presentations by research oncologist Pawel Kalinski, MD, PhD, at major scientific meetings such as the Annual Meeting of the American Association of Immunologists and the U.S.-Poland Science and Technology Symposium. These presentations discuss clinical and preclinical data on Ampligen’s effects on the tumor microenvironment, chemokine modulation, and its selective activation of cancer tissues, as well as the potential of private-public partnerships to advance oncology therapies.
Another key category of AIM ImmunoTech news involves its intellectual property. The company announced a U.S. patent titled “Therapeutic Double Stranded RNA and Methods for Producing the Same,” which covers methods of manufacturing therapeutic dsRNA products, including Ampligen, and provides patent protection for manufacturing until 2041. The company links this patent to a broader portfolio of patents and orphan drug designations that support its development programs in cancer, post-COVID fatigue, endometriosis and other conditions.
Corporate and listing-related updates are also a recurring theme. AIM ImmunoTech has issued news about a 1-for-100 reverse stock split, temporary trading on the OTC Pink under AIMI and AIMID, the removal of a trading suspension, and the resumption of trading on the NYSE American under the symbol AIM. It has also disclosed NYSE American notices of noncompliance with minimum stockholders’ equity requirements and the acceptance of a plan to regain compliance by a specified date. Investors following AIMI can use this news feed to monitor scientific presentations, patent developments, exchange compliance updates, and other material events disclosed in company press releases.
AIM ImmunoTech (NYSE American: AIM) announced a presentation at the U.S.-Poland Science and Technology Symposium 2025 featuring Dr. Pawel Kalinski's discussion on the company's drug Ampligen. The presentation, held from June 17-20, 2025, focused on the potential of private-public partnerships in developing oncology treatments.
Dr. Kalinski, a senior investigator for multiple Ampligen oncology studies, highlighted opportunities for expansion in the United States and Eastern European countries through initiatives like the Translational Research Cancer Centers Consortium. CEO Thomas K. Equels will pursue potential clinical partnerships and licensing agreements in Europe, particularly in Poland, at the upcoming Marie Sklodowska-Curie Symposia in September 2025.
AIM ImmunoTech (OTC Pink: AIMI), an immuno-pharma company specializing in therapeutics for cancers, immune disorders, and viral diseases including COVID-19, has announced its transition to trading under the ticker AIMI on the Pink Open Market effective April 07, 2025.
The company also confirmed its upcoming Special Meeting scheduled for April 30, 2025, where a reverse split proposal will be discussed. Shareholders can find detailed information in AIM's Definitive Proxy Statement filed on April 2, 2025.